On May 24, 2023 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, reported that Eric Elenko, Ph.D., Chief Innovation Officer, and Julie Krop, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7th, 2023 at 1:30pm EDT / 6:30pm BST (Press release, PureTech Health, MAY 24, 2023, View Source [SID1234632006]). A webcast of the presentation will be available at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 24, 2023 (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE technology, reported that management will present at the annual Biotechnology Innovation Organization (BIO) International Convention, to be held in-person in Boston, MA, June 5 – 8, 2023 (Press release, Pulmatrix, MAY 24, 2023, View Source [SID1234632005]). Presentation details are below. Pulmatrix management will also be available for one-on-one meetings throughout the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BIO International Convention Presentation Information:

Format: Live presentation
Presenter: Ted Raad, Chief Executive Officer, Pulmatrix, Inc.
Date: Monday, June 5, 2023
Time: 12:45 PM EDT
Location: Room 104A

Following the live presentation at BIO on June 5th, the presentation will be posted on Pulmatrix’s website.

On May 24, 2023 Processa Pharmaceuticals presented its corporate presentation (Presentation, Processa Pharmaceuticals, MAY 24, 2023, View Source [SID1234632003]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 24, 2023 Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS-based in vivo gene editing and ex vivo allogeneic CAR T therapies, reported that the Company will participate in the Stifel Genetic Medicines Day taking place May 30, 2023 (Press release, Precision Biosciences, MAY 24, 2023, View Source [SID1234632002]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the virtual fireside chat are as follows:
Date: Tuesday, May 30, 2023
Time: 2:25 PM ET

The fireside chat will be available via a live webcast accessible on Precision’s website in the Investors section under Events & Presentations on May 30, 2023: View Source An archived replay will be available for approximately 30 days following the event.

On May 24, 2023 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL RNAi platform technology is designed to make immune cells more effective in killing tumor cells, reported its clinical development partner, AgonOx, Inc, in collaboration with Providence Cancer Institute, has completed the site initiation visit and can commence with patient accrual (Press release, Phio Pharmaceuticals, MAY 24, 2023, View Source [SID1234632001]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The clinical trial will assess the safety and the potential for enhanced therapeutic benefit from the administration of Phio’s PH-762 treated ‘double positive’ (DP) CD8 tumor infiltrating lymphocytes (TILs) in patients with melanoma and other advanced solid tumors. The trial will be conducted at Providence Cancer Institute in Portland, Oregon, by Principal Investigator Brendan Curti, MD, Medical Oncologist and Robert W. Franz Endowed Chair for Clinical Research at the Earle A. Chiles Research Institute, a division of Providence.

"With both regulatory clearance and the completion of the site initiation visit this study can now proceed and we are excited to test PH-762 combined with this new TIL therapy," said Andrew Weinberg, PhD, President and CSO at AgonOx and Member at the Earle A. Chiles Research Institute, Providence Cancer Institute.

"With the initiation of this clinical trial, Phio continues to advance the development of improved cell therapies for oncologic indications. We are pleased with our ongoing collaboration with AgonOx and the Providence Cancer Institute and look forward to continued progress," said Robert Bitterman, Phio’s President and CEO.

Phio recently received FDA clearance to initiate a clinical trial of intratumoral PH-762 in patients with cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The trial is expected to commence in the second half of 2023.